Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 402
- Registration Number
- NCT01175811
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kung City, Taiwan
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01136746
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 125
- Registration Number
- NCT00993473
- Locations
- 🇮🇳
Sanofi-Aventis Investigational Site Number 356001, Bangalore, India
🇮🇳Sanofi-Aventis Investigational Site Number 356004, Karnal, India
🇲🇽Sanofi-Aventis Investigational Site Number 484003, Monterrey, Mexico
A Study on the Effect of 2 Pen Devices on HbA1c
- Conditions
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 263
- Registration Number
- NCT00985712
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00979875
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1036
- Registration Number
- NCT00960661
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT00883558
- Locations
- 🇺🇸
UNC Diabetes Care Center/Highgate Specialty Center, Durham, North Carolina, United States
🇺🇸West Olympia Internal Medicine, Olympia, Washington, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT00862849
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Biodel
- Target Recruit Count
- 15
- Registration Number
- NCT00849576
- Locations
- 🇩🇪
IKFE, Parcusstrasse 8, Mainz, Germany
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 130
- Registration Number
- NCT00700622
- Locations
- 🇺🇸
AM Diabetes and Endocrinology Center, Barrtlett, Tennessee, United States
🇺🇸Diabetes Research Center -Fletcher Allen Health Care, South Burlington, Vermont, United States
🇺🇸The Whittier Institute for Diabetes Clinical Trials, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.